Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, and Severance Biomedical Science Institute, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
Yonsei Med J. 2013 Sep;54(5):1119-26. doi: 10.3349/ymj.2013.54.5.1119.
The aim of this study was to find an optimal range of activated clotting time (ACT) during off-pump coronary artery bypass surgery (OPCAB) yielding ischemic protection without the risk of hemorrhagic complications in patients with recent exposure to dual antiplatelet therapy.
Three hundred and five patients who received aspirin and clopidogrel within 7 days of isolated multi-vessel OPCAB were retrospectively studied. Combined hemorrhagic and ischemic outcome was defined as the occurrence of 1 of the following: significant perioperative bleeding (>30% of estimated blood volume), transfusion of packed red blood cell (pRBC) ≥ 2 U, or myocardial infarction (MI). This was compared in relation to the tertile distribution of the time-weighted average ACT-212-291 sec (first tertile), 292-334 sec (second tertile), 335-485 sec (third tertile).
The amount of perioperative blood loss was 937 ± 313 mL, 1014 ± 340 mL, and 1076 ± 383 mL, respectively (p=0.022). Significantly more patients in the third tertile developed MI (4%, 4%, and 12%, respectively, p=0.034). The incidence of significant perioperative blood loss and transfusion of pRBC ≥ 2 U were lower in the first tertile than those of other tertiles without statistical significance. In the multivariate analysis, the first tertile was associated with a 52% risk reduction of combined hemorrhagic and ischemic outcomes (95% confidence interval: 0.25-0.92, p= 0.027).
A lower degree of anticoagulation with a reduced initial heparin loading dose should be carefully considered for patients undergoing OPCAB who have recently been exposed to clopidogrel.
本研究旨在寻找一个在非体外循环冠状动脉旁路移植术(OPCAB)期间激活凝血时间(ACT)的最佳范围,在近期接受双联抗血小板治疗的患者中既能提供缺血保护,又没有出血并发症的风险。
回顾性研究了 305 例在接受阿司匹林和氯吡格雷治疗后 7 天内接受单纯多血管 OPCAB 的患者。将联合出血和缺血结果定义为以下任何一种情况的发生:围手术期大量出血(>估计血容量的 30%)、输注浓缩红细胞(pRBC)≥2 U 或心肌梗死(MI)。将这些结果与时间加权平均 ACT-212-291 秒的三分位分布(第一三分位,292-334 秒)、292-334 秒(第二三分位)、335-485 秒(第三三分位)进行比较。
围手术期出血量分别为 937±313 mL、1014±340 mL 和 1076±383 mL(p=0.022)。第三三分位组中发生 MI 的患者明显更多(分别为 4%、4%和 12%,p=0.034)。与其他三分位相比,第一三分位的围手术期大量出血和输注 pRBC≥2 U 的发生率较低,但无统计学意义。在多变量分析中,第一三分位与联合出血和缺血结果的风险降低 52%相关(95%置信区间:0.25-0.92,p=0.027)。
对于近期接受过氯吡格雷治疗的接受 OPCAB 的患者,应仔细考虑减少初始肝素负荷剂量以降低抗凝程度。